Aerie’s glaucoma drug Rhopressa wins backing from U.S. FDA panel

(Reuters) – The benefit of Aerie Pharmaceuticals Inc's experimental glaucoma treatment outweighs the risks and the drug should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Friday.
Original Article

more recommended stories